Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Against the trial’s posted results

• Same as the trial’s posted resultThis paper HR 1.02 (0.87–1.21)Posted, primary outcome HR 1.02 (0.87–1.21), p = 0.80Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary Syndrome (ACS), or Symptom-driven Coronary or Cerebral Revascularization